This commentary reflects on reasonable biomarker expectations in ASD by addressing three key questions: What is a biomarker? What is required for a biomarker in ASD? How can biomarkers be useful in ASD? In addressing these queries, a path forward emerges based on clear definition of the objective for any given ASD biomarker and evaluation of each biomarker relative to current best practices.
Keywords: Autism spectrum disorder; Biomarkers; Clinical trials; Endpoints.
Copyright © 2021. Published by Elsevier B.V.